Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer Res. 2013 Feb 22;73(5):1547–1558. doi: 10.1158/0008-5472.CAN-12-3343

Figure 6.

Figure 6

CD8+ T-cells are required for therapeutic efficacy of Lip-αCD137+Lip-IL-2Fc. Mice (n=6–10) bearing B16F10 tumors on both hind flanks were injected i.p. with anti-CD8a or anti-NK1.1 depleting antibodies (400 μg/dose) on days 7/12/16, and treated i.t. at one flank on days 9/12/16 (arrows) with PBS or Lip-αCD137+Lip-IL-2Fc. A. Average growths of liposome-treated tumors and contralateral untreated tumors with or without CD8/NK cell depletion. *p=0.01, **p=0.006. B. Kaplan-Meier survival curve of dual-tumor-bearing mice treated with PBS or Lip-αCD137+Lip-IL-2Fc therapy (arrows), with or without cell depletion. *p=0.004, **p<0.0001.